A class of prodrug compounds activated by glutathione for synergistic enhancement of photothermal / chemotherapy and its preparation method and application

Through L-glutathione activation of synergistically enhanced photothermal/chemotherapy prodrug compounds, the problem of photothermal/chemotherapy combined treatment in the prior art is difficult to achieve selective killing in tumor treatment, and achieve high efficiency for cancer cells It has good industrialization potential.

CN115557877BActive Publication Date: 2024-11-05DALIAN UNIV OF TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202211337253.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-28
Publication Date
2024-11-05
Estimated Expiration
2042-10-28

AI Technical Summary

Technical Problem

The existing combination photothermal/chemotherapy treatment system is difficult to achieve efficient selective killing of normal cells and cancer cells in tumor treatment, and conventional chemotherapy methods will lead to drug resistance and side effects.

Method used

Activate prodrug compounds that synergistically enhance photothermal/chemotherapy through L-glutathione (GSH), and use GSH to synchronize photosensitizers and chemotherapy drugs to achieve selective killing of cancer cells and ensure GSH through specific linkage bonds high responsiveness and selectivity.

Benefits of technology

It achieves precise selective killing of cancer cells, reduces the toxic side effects on normal cells, improves the synergistic effect of photothermal treatment and chemotherapy, and the preparation method is simple and easy to industrialize.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115557877B_ABST
    Figure CN115557877B_ABST
Patent Text Reader

Abstract

The present invention discloses a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds and their preparation methods and applications in selective killing of cancer cells and / treatment of tumors. The first purpose is to provide a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds, which synchronously activate photosensitizers and chemotherapeutic drugs through L-glutathione (GSH) to achieve selective killing of cancer cells and normal cells. The second purpose is to provide a method for preparing a prodrug compound, in an anhydrous system, first reacting an indole compound containing an R2 group with 2-chloro-3-(hydroxymethylene)-1-cyclohexene-1-formaldehyde to obtain compound IV; then reacting compound IV with an aniline compound substituted with R3 as a para position to obtain compound V; then reacting compound V with triphosgene and a compound containing an R4 group to obtain compound VI; finally, activating a compound containing an R5 group and continuing to react with compound VI to obtain a target prodrug compound.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds and a preparation method and application thereof. Background Art

[0002] Photothermal therapy (PTT) is a precise, minimally invasive, and side-free cancer treatment strategy, in which photosensitizers convert light energy into heat through non-radiative transitions to induce cancer cell necrosis. However, the upregulation of heat shock proteins (HSPs) during PTT will increase the heat resistance of cancer cells, greatly limiting the treatment efficiency and even causing tumor recurrence. Alkylating agents, as commonly used chemotherapy drugs, kill cancer cells by covalently binding to biomacromolecules (DNA, RNA, enzymes) to inactivate them or break DNA chains, which has a more thorough killing effect and makes up for the lack of PTT killing efficiency. However, conventional chemotherapy methods can cause the body to develop drug resistance, and when the drug concentration is too high, it will have toxic side effects on normal cells. It is generally believed that hyperthermia (i.e., temperature exceeding 41.5°C) can increase the degree of DNA alkylation of alkylating agents and enhance the killing effect of cancer cells. Therefore, the PTT combined with chemotherapy anti-tumor system overcomes the shortcomings of a single treatment mode and has good application prospects.

[0003] Most of the reported work is to mix chemotherapeutic drugs with photothermal photosensitizers and then encapsulate them into nanocarriers to achieve the combination of PTT and chemotherapy. This combined treatment system is undoubtedly more effective than single treatment methods. However, since the activity of photothermal photosensitizers and chemotherapeutic drugs is not inhibited, they can act on various cells after being released from nanoparticles, and may not be able to achieve efficient selective killing of normal cells and cancer cells. Therefore, this strategy has limited efficiency in tumor treatment.

[0004] Prodrugs usually refer to substances that are non-toxic to normal cells through chemical modification but are toxic when activated specifically in the tumor microenvironment. They are a wise strategy to improve tumor selectivity and reduce side effects. L-glutathione (GSH) is one of the typical overexpressed biomarkers in cancer cells. It can break disulfide bonds and is an ideal bioactivator for activation-type therapy. GSH-activatable probes and prodrugs connected by disulfide bonds can greatly reduce their toxic side effects and achieve differentiation and selective killing of normal cells and cancer cells. Summary of the invention

[0005] In view of the problem that it is difficult to achieve efficient selective killing of normal cells and cancer cells in the prior art, the first object of the present invention is to provide a class of glutathione-activated synergistically enhanced photothermal / chemotherapy prodrug compounds, which synchronously activate photosensitizers and chemotherapeutic drugs through L-glutathione (GSH) to achieve selective killing of cancer cells and normal cells.

[0006] The second object of the present invention is to provide a method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds, which has the advantages of easy availability of compound raw materials, simple preparation, and easy industrialization.

[0007] The third object of the present invention is to provide a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds for use in the preparation of tumor treatment preparations, which have the ability to synchronously activate photothermal photosensitizers and chemotherapy drugs, selectively kill cancer cells, and achieve the effect of synergistic promotion of photothermal therapy and chemotherapy.

[0008] To achieve the first objective, the present invention provides the following technical solution: a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds, wherein the prodrug compound has the following general formula I structure:

[0009]

[0010] Wherein, R1 is H, CH3, I, NO2 or CF3;

[0011] R2 is CH3, CH2CH3, (CH2)2CH3, (CH2)2COOH or (CH2)4SO3Na;

[0012] R3 is O or S;

[0013] R4 is -SS- or -CC-;

[0014] R5 is -N[(CH2CH2) m X]2, wherein X is selected from halogen, hydroxyl, mercapto or nitro; m is an integer from 1 to 4, and R5 is a para substituent.

[0015] To achieve the above second purpose, the present invention provides the following technical solution: a method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds, in an anhydrous system, by the following method to prepare the compound of formula I:

[0016] (1) Preparation of the compound of formula IV

[0017]

[0018] An indole compound II containing an R2 group reacts with 2-chloro-3-(hydroxymethylene)-1-cyclohexene-1-carboxaldehyde III in the presence of a first anhydrous organic solvent and a first catalyst to obtain a compound of formula IV;

[0019] (2) Preparation of compounds of formula V

[0020]

[0021] The compound of formula IV reacts with an aniline compound having R3 as a para-substituted compound in the presence of a second anhydrous organic solvent to obtain a compound of formula V;

[0022] (3) Preparation of compounds of formula VI

[0023]

[0024] In the presence of a third anhydrous organic solvent and a third catalyst mixed system, the compound of formula V reacts with triphosgene to obtain an intermediate, and the intermediate reacts with a compound containing an R4 group to obtain a compound of formula VI;

[0025] (4) Preparation of compounds of formula I

[0026]

[0027] The compound containing the R5 group is activated under the action of the fourth catalyst and the fourth anhydrous organic solvent, and then the compound of formula VI is added to continue the reaction to obtain the compound of formula I.

[0028] Furthermore, in step (1), the molar ratio of the indole compound II to 2-chloro-3-(hydroxymethylene)-1-cyclohexene-1-carbaldehyde III is 1:(2.5-3), the reaction time is 3-5 hours, and the reaction temperature is 25-60°C; the first anhydrous organic solvent is selected from acetic anhydride, ethanol or acetonitrile; and the first catalyst is selected from anhydrous sodium acetate and anhydrous potassium carbonate.

[0029] Furthermore, in step (2), the molar ratio of the compound of formula IV to the aniline compound having R3 as a para-substituent is 1:2, the reaction time is 4-5 hours, the reaction temperature is 20-40°C, and the second anhydrous organic solvent is selected from anhydrous DMF or anhydrous acetonitrile.

[0030] Furthermore, in step (3), the molar ratio of the compound of formula V to triphosgene is 2:(1-1.5), the reaction time of the compound of formula V and triphosgene is 2-3h, the third anhydrous organic solvent used is selected from anhydrous dichloromethane or anhydrous acetonitrile, and the third catalyst is selected from 4-dimethylaminopyridine, N,N'-diisopropylethylamine, triethylamine or pyridine.

[0031] Furthermore, in step (3), the reaction time of the intermediate and the compound containing the R4 group is 12-24 hours, and the reaction temperature is 20-30°C.

[0032] Further, in step (4), the activation reaction is carried out in an ice bath for 2-3 hours, the fourth catalyst used is selected from N,N'-dicyclohexylcarbodiimide, 4-dimethylaminopyridine or triethylamine, and the fourth anhydrous organic solvent is anhydrous dichloromethane or anhydrous DMF;

[0033] The reaction time of the activated reactant and the compound of formula VI is 12-24 hours, and the reaction temperature is 20-30°C.

[0034] To achieve the above third purpose, the present invention provides the following technical solution: the application of a class of glutathione-activated synergistically enhanced photothermal / chemotherapy prodrug compounds, wherein the glutathione-activated synergistically enhanced photothermal / chemotherapy prodrug compounds are used for selective killing of cancer cells and / or treating tumors, wherein the tumors are glutathione-overexpressing tumors.

[0035] In summary, the present invention has the following beneficial effects:

[0036] First, the absorption and emission wavelengths of the glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compound prepared by the present invention are around 800 nm, and it has excellent near-infrared photosensitizing dye properties; and the introduction of a specifically responsive linker in the prodrug compound ensures that it has a sensitive response and high selectivity to GSH in vitro.

[0037] Second, the present invention combines photothermal photosensitizers with chemotherapeutic drugs. GSH is a substance overexpressed by cancer cells. After the prodrug is activated by GSH, it releases cyanine dye photosensitizers and chemotherapeutic drugs, which can simultaneously activate the photosensitizer and chemotherapeutic drugs, and the two treatment methods promote each other synergistically.

[0038] Third, after activation, cyanine dyes have a PET effect, which quenches fluorescence and releases the absorbed light energy in the form of non-radiative transitions, thereby improving the photothermal conversion capacity of the photosensitizer; through specific activation, chemotherapy drugs are precisely released in cancer cells, showing excellent cancer cell selectivity. A more in-depth discussion was conducted on the synergistic enhancement effect of photothermal therapy and chemotherapy. The photothermal effect of cyanine dyes can improve the alkylation efficiency of chemotherapy drugs and improve the chemotherapy effect. Similarly, chemotherapy drugs can reduce the expression of heat shock proteins during photothermal treatment and improve photothermal therapy. The two work together to greatly promote the killing effect of cancer cells.

[0039] Fourth, it has good biocompatibility. In the mouse tumor inhibition experiment, the prodrug can image and treat mouse tumors, showing excellent tumor inhibition effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0041] Figure 1 The absorption and fluorescence spectra of Cy-SS-Cbl and Cy-NH2 disclosed in the embodiments of the present invention; A is the absorption spectrum; B is the fluorescence spectrum;

[0042] Figure 2 Liquid chromatography of Cy-NH2, Cy-SS-Cbl and Cy-SS-Cbl+GSH disclosed in the embodiments of the present invention;

[0043] Figure 3 The fluorescence change of Cy-SS-Cbl and GSH mixed in the embodiment of the present invention from 0 to 150 min;

[0044] Figure 4 is selective, from left to right: control; alanine; arginine; glutamic acid; serine; threonine; tryptophan; tyrosine; potassium ion; calcium ion; sodium ion; magnesium ion; dithiothreitol; cysteine; homocysteine; glutathione;

[0045] Figure 5 The figure is a temperature rise curve diagram of Cy-NH2 disclosed in the embodiment of the present invention under 808nm laser irradiation; A is a temperature rise curve diagram of Cy-NH2 with different concentrations; B is a temperature rise curve diagram of Cy-NH2 with different laser intensities;

[0046] Figure 6 The Cy-SS-Cbl, Cy-NH2 and ICG disclosed in the embodiment of the present invention were respectively irradiated with 808 nm laser (0.5 W / cm -2 ) Temperature rise curve at a concentration of 40 μM under irradiation;

[0047] Figure 7 The photothermal heating-cooling curves of Cy-SS-Cbl and Cy-NH2 disclosed in the embodiments of the present invention;

[0048] Figure 8 The cell survival rates of Hela cells incubated with different concentrations of Cy-NH2, Cy-SS-Cbl, and Cy-SS-Cbl+NEM; A is the cell survival rate in the dark; B is the cell survival rate under 808nm laser (0.5W / cm -2 , 5min) cell survival rate after irradiation;

[0049] Fig. 9 The Cy-NH2 disclosed in the embodiment of the present invention is respectively in the dark and 808nm laser (0.5W / cm -2 , 5min) for the cell survival rate of Hela, HepG2, MCF-7, 4T1 and 3T3 cells;

[0050] Fig.10 The Cy-SS-Cbl disclosed in the embodiment of the present invention is respectively in the dark and 808nm laser (0.5W / cm -2 , 5min) for the cell survival rate of Hela, HepG2, MCF-7, 4T1 and 3T3 cells;

[0051] Fig.11 The gel electrophoresis images of the alkylation of pBR322 DNA by Cy-NH2 and Cy-SS-Cbl disclosed in the embodiments of the present invention under light and dark conditions respectively;

[0052] Fig.12 The confocal imaging of Hela cell γ-H2AX immunofluorescence staining by Cy-NH2 and Cy-SS-Cbl disclosed in the embodiments of the present invention under light and dark conditions respectively;

[0053] Fig.13 Gel electrophoresis imaging of HSP70 expression in Hela cells under light and dark conditions using Cy-NH2 and Cy-SS-Cbl disclosed in the embodiments of the present invention, respectively, wherein: (1) PBS; (2) PBS+light; (3) Cy-SS-Cbl; (4) Cy-NH2+light; (5) Cy-SS-Cbl+light;

[0054] Fig.14 It is the curve diagram of tumor volume change of mice;

[0055] Fig.15 The bar graph shows the average tumor weight on day 22 after treatment. DETAILED DESCRIPTION

[0056] To make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the following will be combined with the appended drawings of the embodiments of the present invention. Figure 1-Figure 15 , the technical solutions in the embodiments of the present invention are clearly and completely described. Obviously, the described embodiments are part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0057] The chemicals involved in this application are all from Anage or Aladdin Chemical Reagent Company, the biological consumables fetal bovine serum, trypsin, and DMEM culture medium are purchased from Giboca, the cells used are from the ATCC cell bank, and other raw materials are commercially available without special requirements.

[0058] Example

[0059] Example 1

[0060] This embodiment discloses the preparation of a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds in which R1 is H, R2 is -(CH2)4SO3Na, R3 is S; R4 is -SS-, and R5 is -N[(CH2CH2)Cl]2. The synthesis method is as follows:

[0061]

[0062] (1) Under N2 protection, 2,3,3-trimethyl-3H-indole (4.78 g, 30 mmol) and 1,4-butanesultone (14.25 g, 90 mmol) were dissolved in 1,2-dichlorobenzene (25 mL), heated to 110°C and stirred for 12 hours. The reaction mixture was cooled to room temperature, the crude product was washed with acetone (150 mL), and then cooled in an ice bath for a few minutes, the solvent was filtered off, and the residue was collected to obtain compound 1, which is an indole compound with R1 being H and R2 being -(CH2)4SO3Na, pink crystals with a yield of 97%;

[0063] Under N2 protection, compound 1 (1.36 g, 4.6 mmol), 2-chloro-1-formyl-3-hydroxymethylcyclohexene (0.344 g, 2 mmol), and anhydrous sodium acetate (0.377 g, 4.6 mmol) were mixed in acetic anhydride (15 mL) and stirred at room temperature for 3-4 hours. After the reaction was completed, the solvent was evaporated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (dichloromethane: methanol = 10: 1, v / v) to obtain compound 2, a green solid, with a yield of 82%;

[0064] (2) Under N2 protection, compound 2 (0.374 g, 0.5 mmol) and 4-aminothiophenol (0.25 g, 2 mmol) were dissolved in anhydrous DMF (10 mL) and stirred at room temperature for 4 h. The reaction solution was poured into ether (150 mL), allowed to stand for precipitation, and filtered to obtain a blue-black solid. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 7:1, v / v) to obtain compound Cy-NH2 as a dark blue solid with a yield of 91%;

[0065] High resolution mass spectrum of compound Cy-NH2: m / z C 44 H 52 N3O6S3Na([M-Na]- ): Calculated value 814.3024, tested value 814.3027.

[0066] The H-NMR spectrum analysis of compound Cy-NH2 is as follows: 1 H NMR (400MHz, DMSO-d6) δ8.72(d,J=14.1Hz,2H),7.55(d,J=7.3Hz,2H),7.46–7.36(m,4H),7.23(t,J=7.2Hz,2H),6.98(d,J=8.3Hz,2H),6.52(d,J=8.3 Hz,2H),6.34(d,J=14.2Hz,2H),4.17(d,J=6.1Hz,4H),2.72(s,4H),1.83– 1.67(m,10H),1.53(s,12H),1.45(d,J=7.7Hz,2H),1.20(d,J=22.5Hz,4H).

[0067] The NMR carbon spectrum analysis of compound Cy-NH2 is as follows: 13 C NMR (126MHz, DMSO-d6) δ171.63,152.26,147.45,145.53,142.13,141.03,133.28,128.48,128.00,124 .74,122.28,120.91,115.03,111.34,101.54,50.68,48.68,43.58,27.35,26.04,25.81,22.50,20.57.

[0068] (3) Under N2 protection, Cy-NH2 (0.2 g, 0.24 mmol) and N,N-diisopropylethylamine (0.078 g, 0.6 mmol) were dissolved in anhydrous CH2Cl2 (10 mL), stirred for 10 min in an ice bath, then triphosgene (0.036 g, 0.12 mmol) was dissolved in anhydrous CH2Cl2 (5 mL), added dropwise to the reaction system, and stirred for 2-3 h in an ice bath; unreacted phosgene was removed by gas replacement, 2,2'-dithiodiethanol (0.185 g, 1.2 mmol) was dissolved in anhydrous CH2Cl2 (10 mL), added dropwise to the reaction system, and stirred overnight at room temperature. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane: methanol = 10:1, v / v) to obtain compound 3 as a blue-green solid with a yield of 46%;

[0069] High resolution mass spectrum of compound 3: m / z C 49 H 60 N3O9S5Na([M-Na] -): Calculated value 994.2939, tested value 994.2946.

[0070] The H-NMR spectrum analysis of compound 3 is as follows: 1 H NMR (600MHz, DMSO-d6) δ9.71 (s, 1H), 8.63 (d, J = 14.1Hz, 2H), 7.53 (d, J = 7.4Hz, 2H), 7.43 (t, J = 8.6 Hz,4H),7.38(t,J=7.6Hz,2H),7.21(dd,J=19.9,8.1Hz,4H),6.37(d,J=14.2Hz,2H),5.76(s,1H),4 .27(t,J=6.3Hz,2H),4.17(d,J=6.9Hz,4H),3.60(dd,J=12.0,6.3Hz,2H),2.97(t,J=6.3Hz,2H),2 .78(dd,J=14.3,7.8Hz,4H),1.81-1.68(m,10H),1.45(s,12H),1.34(d,J=9.1Hz,2H),1.23(s,4H).

[0071] The NMR carbon spectrum analysis of compound 3 is as follows: 13 C NMR (126MHz, DMSO-d6) δ171.77,153.10,149.58,145.09,142.09,141.06,133.32,129.67,128.49,126.46,124.83,122.30, 111.44,101.75,62.08,59.35,54.88,50.68,48.69,45.46,45.42,41.03,36.79,31.25,27.24,26.08,25.82,22.50,20.46.

[0072] (4) Under N2 protection, chlorambucil (60.9 mg, 0.2 mmol), DCC (62 mg, 0.6 mmol) and DMAP (12.2 mg, 0.1 mmol) were dissolved in anhydrous CH2Cl2 (5 mL), stirred at 0°C for 4 h, and then compound 3 (102 mg, 0.1 mmol) was added to the reaction system, and stirred at room temperature in the dark for 48 h. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane: methanol = 9:1, v / v) to obtain the target compound Cy-SS-Cbl as a dark green solid with a yield of 55%.

[0073] High-resolution mass spectrum of target compound Cy-SS-Cbl: m / z C 63 H 77 Cl2N4O10 S5Na([M-Na] - ): Calculated value 1279.3626, tested value 1279.3650.

[0074] The H-NMR spectrum analysis of compound Cy-SS-Cbl is as follows: 1 H NMR (500MHz, DMSO-d6) δ9.73(s,1H),8.60(d,J=14.0Hz,2H),7.50(d,J=7.3Hz,2H),7.41(d,J=8.0Hz,4H),7.36( t,J=7.6Hz,2H),7.19(dd,J=18.8,7.8Hz,4H),6.97(d,J=7.9Hz,2H),6.62(d,J=7.9Hz,2H),6.34(d,J=14.2Hz,2H ),4.24(t,J=6.2Hz,2H),4.20(t,J=6.1Hz,2H),4.15(s,4H),3.68–3.61(m,8H),2.94(dd,J=14.5,6.6Hz,4H),2.7 4(s,4H),2.41(t,J=7.5Hz,2H),2.23(t,J=7.2Hz,2H),1.77–1.69(m,10H),1.41(s,14H),1.22(d,J=11.3Hz,4H).

[0075] The NMR carbon spectrum analysis of compound Cy-SS-Cbl is as follows: 13 C NMR(126MHz,DMSO-d6)δ173.07,172.29,153.61,150.13,145.60,144.99,142.58 ,141.57,137.56,133.84,129.94,129.80,129.01,126.97,125.36,122.81,120.0 7,112.42,111.94,102.26,72.75,62.50,62.02,60.71,52.71,51.17,49.21,44.17,41.67,37.27,36.97,33.69,33.32,27.76,26.99,26.58,26.34,22.99,21.00.

[0076] Performance testing

[0077] 1. In the preparation process of the above examples, 3 mM stock solutions of the prepared Cy-SS-Cbl and Cy-NH2 were prepared respectively, and their absorption and fluorescence spectra at a concentration of 4 μM were tested in PBS buffer (0.01 mol / L PBS, PBS / DMSO=9 / 1, v / v).

[0078] The absorption spectrum was tested using a UV-Vis 3012 spectrophotometer, as shown in the following figure. Figure 1 As shown, it can be seen that Cy-SS-Cbl and Cy-NH2 have similar absorption spectra, and the maximum absorption wavelength is around 800nm.

[0079] Use a fluorescence spectrometer to test the fluorescence spectrum, as follows Figure 1 As shown in the figure, it can be seen that the fluorescence of Cy-NH2 is significantly quenched relative to Cy-SS-Cbl due to the PET effect generated by the amino group. Therefore, it can be inferred that the light energy absorbed by Cy-NH2 is mainly released in the form of non-radiative transition heat generation.

[0080] 2. Glutathione synchronous activation mechanism and post-response fluorescence change and selectivity testing

[0081] 2.1. In the preparation process of the above embodiment, the prepared Cy-NH2 and Cy-SS-Cbl were monitored by HPLC for absorption at 254nm in the mobile phase (methanol: water = 9:1 to pure water) within 30 minutes. After Cy-SS-Cbl and GSH were incubated at 37°C for 2h, the absorption change at 254nm was monitored by HPLC in the same manner. GSH was added to Cy-SS-Cbl to obtain Cy-SS-Cbl+GSH, which was then incubated at 37°C and its fluorescence change was detected every 15min. The results are shown in Figure 2 and Figure 3 .

[0082] like Figure 2 As shown in the figure, the liquid chromatography of Cy-NH2, Cy-SS-Cbl and Cy-SS-Cbl+GSH indicates that glutathione can release Cy-NH2 and chemotherapeutic drugs after reacting with Cy-SS-Cbl. Figure 3 As shown, within 0-150 min, excess glutathione will gradually weaken the fluorescence of Cy-SS-Cbl, indicating that glutathione can cut the disulfide bond of Cy-SS-Cbl to release Cy-NH2, achieving the effect of fluorescence quenching.

[0083] 2.2. In the preparation process of the above embodiment, the prepared Cy-SS-Cbl was mixed with alanine, arginine, glutamic acid, serine, threonine, tryptophan, tyrosine, potassium ion, calcium ion, sodium ion, magnesium ion, dithiothreitol, cysteine, homocysteine ​​and glutathione respectively, and the fluorescence change at 820nm was detected after incubation at 37°C for 2h. The detection results are shown in Figure 4 .

[0084] like Figure 4 As shown, when other amino acids and metal ions were added, Cy-SS-Cbl only responded to thiols and had good selectivity.

[0085] Combining the embodiments and Figure 2 as well as Figure 3 It can be seen that the mechanism of the target compound Cy-SS-Cbl prepared in the example responding to glutathione is:

[0086]

[0087] In the embodiment of the present application, the cyanine dye and the chemotherapeutic drug are connected by a disulfide bond, and the glutathione overexpressed in the cancer cells can cut the disulfide bond and synchronously activate Cy-SS-Cbl to release the photothermal photosensitizer and the chemotherapeutic drug.

[0088] 3. Photothermal heating effect test

[0089] 3.1. In the same solvent system (PBS, PBS / DMSO = 8:2 v / v), Cy-NH2 solutions with concentrations of 0, 10 μM, 20 μM, and 40 μM were prepared, respectively, and 808 nm laser (power 0.5 W / cm -2 ) to test the photothermal heating capacity under irradiation. Each sample was irradiated for 5 minutes, and the temperature was recorded every 30 seconds by an infrared camera. The test results are shown in Figure 5 , it can be seen that when the concentration is 40μM, the photothermal heating is the highest.

[0090] 3.2. In the same solvent system (PBS, PBS / DMSO = 8:2 v / v), a 40 μM Cy-NH2 solution was used and an 808 nm laser was used at 0.1 W / cm -2 , 0.2W / cm -2 、0.4W / cm -2 , 0.6W / cm -2 Each sample was irradiated for 5 minutes, and the temperature was recorded every 30 seconds by an infrared camera. The test results are as follows: Figure 5 , when the light intensity is 0.4W / cm -2 and 0.6W / cm -2 , the maximum temperature of the solution is not much different.

[0091] 3.3, Cy-NH2, Cy-SS-Cbl and indocyanine green (ICG) were irradiated with 808 nm laser (0.5 W / cm -2 , 5min) and the test results are as follows Figure 6 , it can be seen that the temperature change of Cy-NH2 (ΔT~24℃) is significantly improved compared with Cy-SS-Cbl (ΔT~16℃) and ICG (ΔT~9℃) after laser irradiation, indicating that Cy-NH2 has a higher photothermal conversion ability.

[0092] 3.4 Study on the heating and cooling process of Cy-NH2 and Cy-SS-Cbl: 40 μM Cy-NH2 and Cy-SS-Cbl solutions were heated by 808 nm laser (0.5 W / cm -2 ) for 5 min, then stop irradiation and cool to room temperature. During this process, the temperature of the solution was recorded every 30 seconds. The test results are as follows: Figure 7 , it can be seen that the photothermal conversion efficiency (η) of Cy-NH2 is 43.15%, which is much higher than that of Cy-SS-Cbl (26.35%).

[0093] 4. Evaluation of cell selectivity and killing effect

[0094] 4.1. Hela cells were cultured in a 37°C, 5% CO2 constant temperature cell culture incubator and cultured in DMEM high glucose medium containing 10% serum and 1% double antibody. The cells were incubated with Cy-NH2, Cy-SS-Cbl, and Cy-SS-Cbl plus glutathione inhibitor N-ethylmaleimide (NEM) at a concentration of 0-40 μM. The test results are shown in Figure 8 ,It can be seen that after incubation with Cy-SS-Cbl at a concentration of 40 μmol / L, the cell survival rate dropped to 62%, while the cell survival rates of other groups were very high, indicating that the released drugs can kill cancer cells.

[0095] After incubation for 4 h, the cells were illuminated with 808 nm laser (0.5 W / cm 2 ) were illuminated, and the killing effect of Cy-SS-Cbl on Hela cells was better than that of Cy-NH2 and Cy-SS-Cbl+NEM groups. The test results are shown in Figure 8 It can be seen that Cy-SS-Cbl has a stronger killing effect on Hela cells than Cy-NH2 and Cy-SS-Cbl+NEM groups. These differences indicate that after Cy-SS-Cbl enters the cell, the disulfide bond is cut by endogenous GSH, and the released Cy-NH2 and Cbl work together to enhance cytotoxicity.

[0096] 4.2. Different types of cancer cells (HepG2, MCF-7, 4T1) and normal cells (3T3) were selected to compare the killing effect of Cy-SS-Cbl on different cells. The test results are shown in Fig. 9 and Fig.10 .

[0097] The four types of cells were incubated with 40 μmol / L Cy-SS-Cbl and Cy-NH2, respectively, and then exposed to light in the dark and at 808 nm laser (0.5 W / cm 2 ) were treated with light. After 24 h, MTT solution (5 mg mL -1 ), after incubation for 4 h, 100 μL DMSO was added and the absorbance at 490 nm was measured;

[0098] Fig. 9 Cy-NH2 was exposed to light in the dark and at 808 nm laser (0.5 W / cm -2 , 5min) irradiation for different cell killing cell survival rate diagram, Fig.10 Cy-SS-Cbl was exposed to light in the dark and at 808 nm laser (0.5 W / cm -2 , 5min) irradiation for different cell killing cell survival rate diagram, from Fig. 9 It can be seen that there is no significant difference in the inhibition rate of Cy-NH2 on tumor cells and normal cells. Fig.10 It can be seen that the toxicity of Cy-SS-Cbl to cancer cells is significantly higher than that to normal cells, which indicates that Cy-SS-Cbl has good cancer cell selectivity.

[0099] 5. Synergistic enhancement mechanism of photothermal and chemotherapy

[0100] 5.1. The pBR322 plasmid DNA was first incubated with GSH (10 mM) for 12 h, and then incubated with Cy-SS-Cbl and Cy-NH2 respectively. The alkylation effect was tested by gel electrophoresis under light / dark conditions. The test results are shown in Fig.11 It can be seen that the chemotherapy drug chlorambucil can alkylate the DNA double strands and kill cancer cells. The degree of alkylation after Cy-SS-Cbl incubation was significantly higher than that of the Cy-NH2 group. After light irradiation, the alkylation effect was further improved, indicating that photothermal can promote the alkylation of chemotherapy drugs.

[0101] 5.2. Further verification by γ-H2AX immunofluorescence staining experiment: Hela cells were incubated with PBS, Cy-NH2 or Cy-SS-Cbl for 4 h. After rinsing the cells with PBS, the cells were treated according to the DNA damage detection kit. Confocal fluorescence imaging was performed and images were collected. The excitation wavelengths of DAPI and γ-H2AX were 405 nm and 488 nm, respectively, and the emission signals were collected in the range of 415-485 nm and 500-545 nm, respectively; the test results are shown in Fig.12 ,It can be seen that under the irradiation of 808nm laser, the fluorescence signal is significantly enhanced and the alkylation ratio is improved.

[0102] 5.3. Hela cells were seeded in 10 cm cell culture dishes and cultured with medium containing Cy-SS-Cbl or Cy-NH2 (20 μM). After incubation at 37°C in the dark for 4 h, the cells were irradiated with 808 nm light for 5 min (0.5 W / cm 2 ). After incubation for 12 h, the cells were lysed on ice for 20 min using RIPA lysis buffer containing protease and phosphatase inhibitors. After the protein concentration was determined by the BCA method, an equal amount of protein was added to each lane of the SDS-PAGE gel for electrophoresis and then transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with the HSP70 primary antibody at 4°C overnight, and then incubated with the peroxidase-labeled goat anti-rabbit HRP secondary antibody at room temperature for 2 h, followed by gel electrophoresis imaging analysis. The detection results are shown in Fig.13 It can be seen that the production of heat shock protein is an important reason limiting photothermal therapy. After the same light treatment, the expression level of HSP70 in the Cy-SS-Cbl group was lower than that in the Cy-NH2 group, indicating that chemotherapy drugs can reduce the expression of heat shock protein and promote photothermal effect.

[0103] 6. Mouse tumor inhibition effect test

[0104] A subcutaneous cervical cancer (Hela) tumor model was established in 6-7 week old SCID / BALB / c female mice. 3 The drug was administered by paratumoral injection and then incubated for 4 h with 808 nm laser (0.5 W cm -2 ) The light treatment was performed for 8 minutes, and the changes in tumor volume were recorded. The test results are shown in Fig.14 and Fig.15 It can be seen that during the entire 21-day treatment cycle, the tumor volume of the Cy-SS-Cbl treatment group gradually decreased and there was no recurrence, while the control group showed an 8-9-fold increase in tumor volume. The experimental results prove that the prodrug has good tumor inhibition ability.

[0105] In summary, it can be seen that the selection of chemotherapeutic drugs and photosensitizers is the key to making the prodrug have excellent properties. During the incubation process, it is particularly important that the prodrug is cut by GSH and activates the chemotherapeutic drugs and photosensitizers at the same time. The two treatment methods can promote each other synergistically, ensuring that the prodrug has a good therapeutic effect.

[0106] Compared with the prior art, the prodrug compound provided by the present invention has the following creative features: excellent near-infrared photosensitizing dye properties; synchronous activation of photosensitizers and chemotherapeutic drugs, and the two treatment methods synergistically promote each other; specific recognition and selective killing of cancer cells.

[0107] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds, characterized in that: The prodrug compound has the following structure of general formula I: Wherein, R1 is H, CH3, I, NO2 or CF3; R2 is (CH2)4SO3Na; R3 is O or S; R4 is -SS-; R5 is -N[(CH2 CH2)Cl]2, and R5 is a para substituent.

2. The method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds according to claim 1, characterized in that: In an anhydrous system, the compound of formula I is prepared by the following method: (1) Preparation of the compound of formula IV An indole compound II containing an R2 group reacts with 2-chloro-3-(hydroxymethylene)-1-cyclohexene-1-carboxaldehyde III in the presence of a first anhydrous organic solvent and a first catalyst to obtain a compound of formula IV; (2) Preparation of compounds of formula V The compound of formula IV reacts with an aniline compound having R3 as a para-substituted compound in the presence of a second anhydrous organic solvent to obtain a compound of formula V; (3) Preparation of compounds of formula VI In the presence of a third anhydrous organic solvent and a third catalyst mixed system, the compound of formula V reacts with triphosgene to obtain an intermediate, and the intermediate reacts with 2,2'-dithiodiethanol to obtain a compound of formula VI; (4) Preparation of compounds of formula I Chlorambucil is activated under the action of a fourth catalyst and a fourth anhydrous organic solvent, and then a compound of formula VI is added to continue the reaction to obtain a compound of formula I.

3. The method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds according to claim 2, characterized in that: In step (1), the molar ratio of the indole compound II to 2-chloro-3-(hydroxymethylene)-1-cyclohexene-1-carbaldehyde III is 1:(2.5-3), the reaction time is 3-5 hours, and the reaction temperature is 25-60°C; the first anhydrous organic solvent is selected from acetic anhydride, ethanol or acetonitrile; and the first catalyst is selected from anhydrous sodium acetate and anhydrous potassium carbonate.

4. The method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds according to claim 2, characterized in that: In step (2), the molar ratio of the compound of formula IV to the aniline compound having R3 as a para-substituent is 1:2, the reaction time is 4-5 hours, the reaction temperature is 20-40° C., and the second anhydrous organic solvent is selected from anhydrous DMF or anhydrous acetonitrile.

5. The method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds according to claim 2, characterized in that: In step (3), the molar ratio of the compound of formula V to triphosgene is 2:(1-1.5), the reaction time of the compound of formula V and triphosgene is 2-3h, the third anhydrous organic solvent used is selected from anhydrous dichloromethane or anhydrous acetonitrile, and the third catalyst is selected from 4-dimethylaminopyridine, N,N'-diisopropylethylamine, triethylamine or pyridine.

6. The method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds according to claim 2, characterized in that: In step (3), the reaction time of the intermediate and 2,2'-dithiodiethanol is 12-24 hours, and the reaction temperature is 20-30°C.

7. The method for preparing a class of glutathione activated synergistically enhanced photothermal / chemotherapy prodrug compounds according to claim 2, characterized in that: In step (4), the activation reaction is carried out in an ice bath for 2-3 hours, the fourth catalyst used is selected from N,N'-dicyclohexylcarbodiimide, 4-dimethylaminopyridine or triethylamine, and the fourth anhydrous organic solvent is anhydrous dichloromethane or anhydrous DMF; The reaction time of the activated reactant and the compound of formula VI is 12-24 hours, and the reaction temperature is 20-30°C.

Citation Information

Patent Citations

  • Photosensitive targeted antineoplastic prodrug for responding to glutathione to kill tumor cells and preparation method and application thereof

    CN107235945A

  • Glutathione-responsive fluorinated boron-dipyrromethene anticancer photosensitizer as well as preparation and application thereof

    CN111233907A

  • Synthesis method of diagnosis and treatment combined molecular lead compound and application of synthesis method

    CN111606839A

  • Cys fluorescent molecular probe for detecting DNA targeting under reduction stress as well as preparation method and application of Cys fluorescent molecular probe

    CN113024436A

  • Theranostic conjugates

    US20220273823A1